标题
Pegylated Liposomal Doxorubicin
作者
关键词
-
出版物
DRUGS
Volume 71, Issue 18, Pages 2531-2558
出版商
Springer Nature
发表日期
2011-12-06
DOI
10.2165/11207510-000000000-00000
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
- (2014) L. Livi et al. JOURNAL OF CHEMOTHERAPY
- Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
- (2012) Joan Bladé et al. Clinical Lymphoma Myeloma & Leukemia
- Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™/Doxil® in patients with hematological tumors
- (2011) H. Richly et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2011) Alessandra Gennari et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
- (2011) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
- (2010) Gabriele Buda et al. ANNALS OF HEMATOLOGY
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
- (2010) A. Poveda et al. ANNALS OF ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) F. Cardoso et al. ANNALS OF ONCOLOGY
- Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
- (2010) Antonio C. Wolff et al. BREAST CANCER RESEARCH AND TREATMENT
- Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
- (2010) Emilio Alba et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma
- (2010) Mary Cianfrocca et al. CANCER
- High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
- (2010) Joshua P. Kesterson et al. CHEMOTHERAPY
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
- (2010) Stephen A. Cannistra JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Delayed Neoplastic and Renal Complications in Women Receiving Long-term Chemotherapy for Recurrent Ovarian Cancer
- (2010) F. Muggia et al. JNCI-Journal of the National Cancer Institute
- Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) J.-L. Harousseau et al. ANNALS OF ONCOLOGY
- Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE
- (2009) C. de la Fouchardiere et al. ANNALS OF ONCOLOGY
- Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
- (2009) Mary E.R. OʼBrien ANTI-CANCER DRUGS
- Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
- (2009) David Rossi et al. ANTI-CANCER DRUGS
- Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer
- (2009) Janos L. Tanyi et al. GYNECOLOGIC ONCOLOGY
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
- (2009) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
- (2009) Christos Christodoulou et al. ONCOLOGY
- Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer
- (2009) Brigitte Mlineritsch et al. Oncology Research and Treatment
- Prognostic factors for multiple myeloma in the era of novel agents
- (2008) J. Blade et al. ANNALS OF ONCOLOGY
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
- (2008) Pieter Sonneveld et al. CANCER
- Pegylated Liposomal Doxorubicin
- (2008) Greg L Plosker DRUGS
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts
- (2008) Roger von Moos et al. EUROPEAN JOURNAL OF CANCER
- British HIV Association guidelines for HIV-associated malignancies 2008
- (2008) M Bower et al. HIV MEDICINE
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
- Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
- (2008) W. C. Zamboni ONCOLOGIST
- Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2in patients with recurrent ovarian and peritoneal cancer
- (2007) Y. YILDIRIM et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started